Relationship between chronic lead toxicity and plasma neurotransmitters in autistic patients from Saudi Arabia

Clinical Biochemistry

Volumn 44, Issue 13, 2011, Pages 1116-1120

  El Ansary, Afaf K ^a,b   Bacha, Abir Ben ^a,b   Ayahdi, Layla Y Al ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Autistic disorder; Dopamine; Gamma Aminobutyric acid; Lead; Serotonin

Indexed keywords

4 AMINOBUTYRIC ACID; DOPAMINE; LEAD; SEROTONIN;

AMINO ACID BLOOD LEVEL; ARTICLE; AUTISM; BRAIN FUNCTION; CELL LEVEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; LEAD BLOOD LEVEL; LEAD POISONING; LONG TERM EXPOSURE; PRESCHOOL CHILD; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SAUDI ARABIA; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SEROTONIN BLOOD LEVEL;

AUTISTIC DISORDER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DOPAMINE; ERYTHROCYTES; GAMMA-AMINOBUTYRIC ACID; HUMANS; LEAD; LEAD POISONING; NEUROTRANSMITTER AGENTS; ROC CURVE; SAUDI ARABIA; SEROTONIN;

EID: 80051695168     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.06.982     Document Type: Article

References (44)

1. Van Naarden Braun K., Pettygrove S., Daniels J., Miller L., Nicholas J., Baio J., Schieve L., Kirby R.S., Washington A., Brocksen S., Rahbar H., Rice C. Evaluation of a methodology for a collaborative multiple source surveillance network for autism spectrum disorders-Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2002. MMWR Surveill Summ 2007, 56:29-40.
2. Mutter J., Naumann J., Schneider R., Walach H., Haley B. Mercury and autism: accelerating evidence?. Neuro Endocrinol Lett 2005, 26:439-446.
3. Mutter J., Naumann J., Guethlin C. Comments on the article "the toxicology of mercury and its chemical compounds" by Clarkson and Magos (2006). Crit Rev Toxicol 2007, 37:537-549.
4. Kern J.K., Jones A.M. Evidence of toxicity, oxidative stress, and neuronal insult in autism. J Toxicol Environ Health B Crit Rev 2006, 9:485-499.
5. Zawia N.H. Transcriptional involvement in neurotoxicity. Toxicol Appl Pharmacol 2003, 190:177-188.
6. Qiu L.B., Ding G.R., Li K.C., Wang X.W., Zhou Y., Zhou Y.C., Li Y.R., Guo G.Z. The role of protein kinase C in the opening of blood-brain barrier induced by electromagnetic pulse. Toxicol 2010, 273:29-34.
7. Tiffany-Castiglioni E. Cell culture models for lead toxicity in neuronal and glial cells. Neurotoxicol 1993, 14:513-536.
8. Boyer E.W., Shannon M. The serotonin syndrome. N Engl J Med 2005, 352:1112-1120.
9. Silbergeld E.K., Miller L.P., Kennedy S., Eng N. Lead, GABA, and seizures: effects of subencephalopathic lead exposure on seizure sensitivity and GABAergic function. Environ Res 1979, 19:371-382.
10. Miller D.T., Paschal D.C., Gunter E.W., Stroud P.E., D'Angelo J. Determination of blood lead with electrothermal atomic absorption using a L'vov platform and matrix modifier. Analyst 1987, 112:1701-1704.
11. Parsons P.J., Slavin W. A rapid Zeeman graphite furnace atomic absorption spectrometric method for the determination of lead in blood. Spectrochim Acta 1993, 48B(No. 6/7):925-939.
12. Pepe M.S. The statistical evaluation of medical tests for classification and prediction. Woxford Statistical Science Series 2003, 28.
13. Zhou X.H., Obuchowski N., McClish D. Statistical Methods in Diagnostic Medicine 2002, Wiley, New York.
14. Wang Q., Luo W., Zheng W., Liu Y., Xu H., Zheng G., Dai Z., Zhang W., Chen Y., Chen J. Iron supplement prevents lead-induced disruption of the blood-brain barrier during rat development. Toxicol Appl Pharm 2007, 219:33-41.
15. Dhossche D.M., Rout U. Are autistic and catatonic regression related? A few working hypotheses involving gaba, Purkinje cell survival, neurogenesis, and ECT. Int Rev Neurobiol 2006, 72:55-79.
16. Schmitz C., van Kooten I.A., Hof P.R., van Engeland H., Patterson P.H., Steinbusch H.W. Autism: neuropathology, alterations of the GABAergic system, and animal models. Int Rev Neurobiol 2005, 71:1-26.
17. McDougle C.J., Erickson C.A., Stigler K.A., Posey D.J. Neurochemistry in the pathophysiology of autism. J Clin Psychiatry 2005, 10:9-18.
18. Hollander E., Dolgoff-Kaspar R., Cartwright C., Rawitt R., Novotny S. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry 2001, 62:530-534.
19. Jr Cook E.H., Arora R.C., Anderson G.M., Berry-Kravis E.M., Yan S.Y., Yeoh H.C., Sklena P.J., Charak D.A., Leventhal B.L. Platelet serotonin studies in hyperserotonemic relatives of children with autistic disorder. Life Sci 1993, 52:2005-2015.
20. Singh V.K., Singh E.A., Warren R.P. Hyperserotoninemia and serotonin receptor antibodies in children with autism but not mental retardation. Biol Psychiatry 1997, 41:753-755.
21. Anderson G.M., Horne W.C., Chatterjee D., Cohen D.J. The hyperserotonemia of autism. Ann NY Acad Sci 1990, 600:331-340.
22. Cross S., Kim S.J., Weiss L.A., Delahanty R.J., Sutcliffe J.S., Leventhal B.L., Jr Cook E.H., Veenstra-Vanderweele J. Molecular genetics of the platelet serotonin system in first-degree relatives of patients with autism. Neuropsychopharmacology 2008, 33:353-360.
23. Piven J., Tsai G.C., Nehme E., Coyle J.T., Chase G.A., Folstein S.E. Platelet serotonin, a possible marker for familial autism. J Autism Dev Disord 1991, 21:51-59.
24. Whitaker-Azmitia P.M. Behavioral and cellular consequences of increasing serotonergic activity during brain development: a role in autism?. Int J Dev Neurosci 2005, 23:75-83.
25. Hadjikhani N. Serotonin, pregnancy and increased autism prevalence: is there a link?. Med Hypotheses 2010, 74:880-883.
26. Chugani D.C., Muzik O., Rothermel R., Behen M., Chakraborty P., Mangner T., da Silva E.A., Chugani H.T. Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys. Ann Neurol 1997, 42:666-669.
27. Murphy D.G., Daly E., Schmitz N., Toal F., Murphy K., Curran S., Erlandsson K., Eersels J., Kerwin R., Ell P., Travis M. Cortical serotonin 5-HT2A receptor binding and social communication in adults with Asperger's syndrome: an in vivo SPECT study. Am J Psychiatry 2006, 163:934-936.
28. West L., Brunssen S.H., Waldrop J. Review of the evidence for treatment of children with autism with selective serotonin reuptake inhibitors. J Spec Pediatr Nurs 2009, 14:183-191.
29. McDougle C.J., Naylor S.T., Goodman W.K., Volkmar F.R., Cohen D.J., Price L.H. Acute tryptophan depletion in autistic disorder: a controlled case study. Biol Psychiatry 1993, 33:547-550.
30. Narita N., Kato M., Tazoe M., Miyazaki K., Narita M., Okado N. Increased monoamine concentration in the brain and blood of fetal thalidomide- and valproic acid-exposed rat: putative animal models for autism. Pediatr Res 2002, 52:576-579.
31. Miyazaki K., Narita N., Narita M. Maternal administration of thalidomide or valproic acid causes abnormal serotonergic neurons in the offspring: implication for pathogenesis of autism. Int J Dev Neurosci 2005, 23:287-297.
32. Smolenskya H.M., Miliab L.D., Ohayonc M.M., Philip P. Sleep disorders, medical conditions, and road accident risk. Accid Anal Prev 2011, 43:533-548.
33. Anderson G.M., Hoshino Y. Neurochemical studies of autism. Handbook of autism and pervasive developmental disorders 1997, 325-343. Wiley, New York. D.J. Cohen, F.R. Volkmar (Eds.).
34. Young J.G., Kavanagh M.E., Anderson G.M., Shaywitz B.A., Cohen D.J. Clinical neurochemistry of autism and associated disorders. J Autism Dev Disord 1982, 12:147-165.
35. Stone J.M., Morrison P.D., Pilowsky L.S. Glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review. J Psychopharmacol 2007, 21:440-452.
36. Wong A.H.C., Van Tol H.H.M. Schizophrenia: from phenomenology to neurobiology. Neurosci Biobehav Rev 2003, 27:269-306.
37. Tsai G., Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 2002, 42:165-179.
38. Deth R., Muratore C., Benzecry J., Power-Charnitsky V.A., Waly M. How environmental and genetic factors combine to cause autism: a redox/methylation hypothesis. NeuroToxicol 2008, 29:190-201.
39. Waly M., Olteanu H., Banerjee R., Choi S.W., Mason J.B., Parker B.S., Sukumar S., Shim S., Sharma A., Benzecry J.M., Power-Charnitsky V.A., Deth R.C. Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal. Mol Psychiatry 2004, 9:358-370.
40. Bondy S.C., Agrawal A.K. The inhibition of central high affinity receptor sites by lead and mercury compounds. Arch Toxicol 1980, 46:249-256.
41. Silbergeld E.K., Hruska R.E. Neurochemical investigations of low level lead exposure. Health Effects of Lead at Low Dose 1980, 135-158. Raven Press, New York. H.L. Needleman (Ed.).
42. Struzyñska L., Chalimoniuk M., Sulkowski G. Changes in expression of neuronal and glial glutamate transporters in lead-exposed adult rat brain. Neurochem Int 2005, 47:326-333.
43. Bouyatas M.M., Gamrani H. Immunohistochemical evaluation of the effect of lead exposure on subcommissural organ innervation and secretion in Shaw's Jird (Meriones shawi). Acta Histochem 2007, 109:421-427.
44. Tavakoli-Nezhad M., Barron A.J., Pitts D.K. Postnatal inorganic lead exposure decreases the number of spontaneously active midbrain dopamine neurons in the rat. Neurotoxicol 2001, 22:259-269.